Novartis Ag (NVS) Accounts Payables (2009 - 2025)

Novartis Ag (NVS) has 14 years of Accounts Payables data on file, last reported at $4.5 billion in Q4 2025.

• Quarterly Accounts Payables rose 1600.34% year-over-year to $4.5 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.5 billion (up 1600.34% YoY) and the FY2025 annual result came in at $4.5 billion, up 1600.34% from the prior year.
• Accounts Payables declined to $4.5 billion in Q4 2025 per NVS's latest filing, from $4.5 billion in the prior quarter.
• The five-year high for Accounts Payables was $5.6 billion in Q4 2021, with the low at -$297.0 million in Q4 2024.
• Average Accounts Payables over 5 years is $1.9 billion, with a median of -$3.0 million recorded in 2021.
• Year-over-year, Accounts Payables slumped 2166.67% in 2022 and jumped 7967.65% in 2023.
• Novartis Ag's Accounts Payables stood at $5.6 billion in 2021, then retreated by 7.33% to $5.1 billion in 2022, then slumped by 104.49% to -$231.0 million in 2023, then decreased by 28.57% to -$297.0 million in 2024, then surged by 1600.34% to $4.5 billion in 2025.
• Business Quant data shows NVS's Accounts Payables at $4.5 billion in Q4 2025, $4.5 billion in Q2 2025, and -$297.0 million in Q4 2024.